モノクローナル抗体療法の市場規模、シェア、成長分析、生産別、供給源別、治療法別、投与別、エンドユーザー別、地域別 - 産業予測、2025～2032年

モノクローナル抗体療法市場規模は、2023年に1,540億5,000万米ドルと評価され、2024年の1,653億米ドルから2032年には2,904億4,000万米ドルに成長し、予測期間中（2025-2032年）のCAGRは7.3％で成長する見通しです。

世界のモノクローナル抗体療法市場は、主にがん、自己免疫疾患、心血管疾患などの慢性疾患の有病率の上昇に牽引され、力強い成長を遂げています。これらの疾患の治療におけるモノクローナル抗体の有効性が、その採用を大きく後押ししています。さらに、人口の高齢化と生活習慣病の増加が市場の拡大に拍車をかけています。技術の進歩により、特異性の高い抗体の生産能力が強化され、治療成績が向上しています。加えて、個別化医療や標的療法が重視されるようになったことで、モノクローナル抗体療法に対する需要が高まっており、この市場は今後数年間で持続的な成長が見込まれます。全体として、これらの動向は、ヘルスケアにおけるモノクローナル抗体の将来が有望であることを示しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

モノクローナル抗体療法市場規模：生産別

• 市場概要
• In vitro
• In vivo

モノクローナル抗体療法市場規模：供給源別

• 市場概要
• 人間
• 人間化
• キメラ
• その他

モノクローナル抗体療法市場規模：治療法別

• 市場概要
• 自己免疫疾患および炎症性疾患
• 腫瘍学
• 血液学
• 眼科
• その他

モノクローナル抗体療法市場規模：投与別

• 市場概要
• 静脈内
• 皮下
• その他

モノクローナル抗体療法市場規模：エンドユーザー別

• 市場概要
• 病院
• 長期ケア施設
• その他
• モノクローナル抗体療法市場規模
• 北米（生産供給治療管理エンドユーザー）
  • 米国
  • カナダ
• 欧州（生産供給治療管理エンドユーザー）
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋（製造供給治療管理エンドユーザー）
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ（生産供給治療管理エンドユーザー）
  • ブラジル
  • その他ラテンアメリカ地域
• 中東およびアフリカ（生産供給治療管理エンドユーザー）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
• 収益の前年比比較（2022-2024）

主要企業プロファイル

• Zoetis Inc.（USA）
• Merck & Co., Inc.（USA）
• Elanco Animal Health Incorporated（USA）
• Boehringer Ingelheim International GmbH（Germany）
• Ceva Sante Animale（France）
• Virbac（France）
• Vetoquinol（France）
• Bayer AG（Germany）
• Novartis AG（Switzerland）
• Eli Lilly and Company（USA）
• Sanofi（France）
• Intervet Inc.（Netherlands）
• Alltech（Ireland）
• Huvepharma（Bulgaria）
• Kemin Industries（USA）
• Novus International（USA）
• Biomin Holding GmbH（Austria）
• ADM Animal Nutrition（USA）
• Adisseo（France）
• DSM（Netherlands）

結論と推奨事項

Monoclonal Antibody Therapy Market size was valued at USD 154.05 Billion in 2023 and is poised to grow from USD 165.3 Billion in 2024 to USD 290.44 Billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).

The global monoclonal antibody therapy market is witnessing robust growth, primarily driven by the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. The effectiveness of monoclonal antibodies in treating these illnesses is significantly boosting their adoption. Furthermore, an aging population coupled with the increase in lifestyle-related diseases is fueling market expansion. Technological advancements have enhanced the production capabilities of highly specific antibodies, thereby improving therapeutic outcomes. Additionally, the growing emphasis on personalized medicine and targeted therapies is amplifying the demand for monoclonal antibody therapies, positioning this market for sustained growth in the coming years. Overall, these trends indicate a promising future for monoclonal antibodies in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Monoclonal Antibody Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Monoclonal Antibody Therapy Market Segmental Analysis

Global Monoclonal Antibody Therapy Market is segmented by production, source, therapy, administration, end user and region. Based on production, the market is segmented into in vitro and in vivo. Based on source, the market is segmented into human, humanized, chimeric and other. Based on therapy, the market is segmented into autoimmune and inflammatory disorders, oncology, hematology, ophthalmology and others. Based on administration, the market is segmented into intravenous, subcutaneous and other. Based on end user, the market is segmented into hospitals, long term care facilities and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Monoclonal Antibody Therapy Market

The Monoclonal Antibody Therapy market is primarily driven by notable advancements in biotechnology and genetic engineering. These developments have been crucial in creating sophisticated monoclonal antibody therapies that exhibit enhanced specificity and efficacy while minimizing side effects. Innovative techniques, including genetic manipulation, enable researchers to tailor antibodies for particular targets, thereby maximizing their therapeutic effectiveness. As a result, these scientific breakthroughs have expanded the applications of monoclonal antibody therapies and significantly improved their success rates in treating various diseases. This continued evolution in biotechnology is essential for the growth and evolution of the monoclonal antibody therapy market.

Restraints in the Monoclonal Antibody Therapy Market

The Monoclonal Antibody Therapy market faces several constraints primarily related to potential side effects and safety issues associated with these treatments. Patients may experience infusion-related reactions during administration, which can lead to discomfort and anxiety. Additionally, there is a risk of immunogenicity, where the patient's immune system reacts against the therapy itself, potentially reducing its effectiveness. Off-target effects may also occur, where the antibody interacts with unintended biological targets, leading to adverse outcomes. To mitigate these concerns, it is essential to implement rigorous safety monitoring, thorough risk assessments, and transparent communication regarding potential side effects, thereby upholding patient safety and trust in these therapies.

Market Trends of the Monoclonal Antibody Therapy Market

The monoclonal antibody therapy market is witnessing a robust trend towards increasing adoption of personalized and targeted therapies. As healthcare shifts towards individualized treatment plans, monoclonal antibodies are at the forefront of this evolution, effectively treating conditions such as cancer, autoimmune disorders, and infectious diseases. The integration of companion diagnostics, genetic profiling, and biomarker identification enhances the development and prescription of these therapies, ensuring more precise treatments that optimize therapeutic efficacy and reduce adverse effects. This growing emphasis on personalized medicine is expected to drive substantial growth in the monoclonal antibody market, reflecting a transformative approach to disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Monoclonal Antibody Therapy Market Size by Production & CAGR (2025-2032)

• Market Overview
• In Vitro
• In Vivo

Global Monoclonal Antibody Therapy Market Size by Source & CAGR (2025-2032)

• Market Overview
• Human
• Humanized
• Chimeric
• Other

Global Monoclonal Antibody Therapy Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Autoimmune And Inflammatory Disorders
• Oncology
• Hematology
• Ophthalmology
• Others

Global Monoclonal Antibody Therapy Market Size by Administration & CAGR (2025-2032)

• Market Overview
• Intravenous
• Subcutaneous
• Other

Global Monoclonal Antibody Therapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Long Term Care Facilities
• Others
• Global Monoclonal Antibody Therapy Market Size & CAGR (2025-2032)
• North America (Production, Source, Therapy, Administration, End User)
  • US
  • Canada
• Europe (Production, Source, Therapy, Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Production, Source, Therapy, Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Production, Source, Therapy, Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Production, Source, Therapy, Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Zoetis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intervet Inc. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alltech (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Huvepharma (Bulgaria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kemin Industries (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novus International (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomin Holding GmbH (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADM Animal Nutrition (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adisseo (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DSM (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations